Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Bayer Aktienges Ads (BAYRY)

Bayer Aktienges Ads (BAYRY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 44,687,796
  • Shares Outstanding, K 3,730,200
  • Annual Sales, $ 48,770 M
  • Annual Income, $ 4,582 M
  • 60-Month Beta 1.15
  • Price/Sales 0.92
  • Price/Cash Flow 3.42
  • Price/Book 1.12
Trade BAYRY with:
  • Price/Earnings ttm 6.39
  • Earnings Per Share ttm 1.86
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/04/20
  • Annual Dividend & Yield 0.53 (4.44%)
  • Most Recent Dividend 0.531 on 04/29/20
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 0.27
  • Number of Estimates 1
  • High Estimate 0.27
  • Low Estimate 0.27
  • Prior Year 0.32
  • Growth Rate Est. (year over year) -15.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.6500 +0.39%
on 10/30/20
14.0400 -16.70%
on 10/01/20
-3.2550 (-21.77%)
since 09/30/20
3-Month
11.6500 +0.39%
on 10/30/20
17.3800 -32.71%
on 08/03/20
-5.1650 (-30.63%)
since 07/30/20
52-Week
11.6500 +0.39%
on 10/30/20
21.5900 -45.83%
on 01/23/20
-7.0750 (-37.69%)
since 10/30/19

Most Recent Stories

More News
Topical Drug Delivery Market Research Report by Application, by End User – Global Forecast to 2025 – Cumulative Impact of COVID-19

The Global is segmented on the lines of its producttype, facility of use, route of administration and regional. Based on product type segmentation it covers formulation, devices.Based on facility of use...

BAYRY : 11.6850 (-2.46%)
CRRTF : 0.3700 (-1.93%)
NVS : 77.48 (-0.76%)
VRX.TO : 30.80 (-3.33%)
Immunity Booster Supplement Market Research Report by Form, by Distribution - Global Forecast to 2025 - Cumulative Impact of COVID-19

, /PRNewswire/ -- Read the full report: The Global Immunity Booster Supplement Market is expected to grow from in 2019 to by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 9.50%. This...

ADM : 45.93 (-7.99%)
BAYRY : 11.6850 (-2.46%)
GLAPF : 10.5000 (unch)
GSK : 33.32 (-1.88%)
NUTR : 41.80 (+0.12%)
OTSKY : 18.4600 (-2.33%)
PFE : 34.98 (-0.85%)
PG : 135.14 (-1.77%)
Finerenone significantly reduced renal and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes

Finerenone significantly reduced renal and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes

BAYRY : 11.6850 (-2.46%)
Global Hemophilia Therapeutics Market- Featuring Bayer AG, CSL Ltd., F. Hoffmann-La Roche Ltd. Among Others

The hemophilia therapeutics market is poised to grow by USD 4.19 billion during 2020-2024 progressing at a CAGR of over 6% during the forecast period.

BAYRY : 11.6850 (-2.46%)
CSLLY : 101.4000 (-2.30%)
Bayer (BAYRY) to Report Q3 Earnings: What's in the Cards?

Bayer (BAYRY) will provide updates on its marketed drugs, earnings and other pipeline candidates when it releases third-quarter 2020 results on Nov 3.

JNJ : 135.29 (-1.38%)
ALKS : 16.35 (+0.43%)
ALNY : 122.30 (-0.83%)
BAYRY : 11.6850 (-2.46%)
Immune Health Supplements Market Worth USD 29.40 Billion at 7.4% CAGR; Rapid Changes in Lifestyles to Bolster Growth, says Fortune Business Insights(TM)

The global immune health supplements market size is likely to grow astonishingly backed by the increasing popularity of non-GMO and organic ingredients amongst the masses. The trend is further resulting...

BAYRY : 11.6850 (-2.46%)
GLAPF : 10.5000 (unch)
USNA : 75.71 (-3.71%)
Orphan Drugs Market to Reach USD 340.84 Billion with 10.5% CAGR by 2027; Increasing Number of Regulatory Approvals will Contribute to Market Growth, says Fortune Business Insights(TM)

The global orphan drugs market size is projected to reach USD 340.84 billion by the end of 2027. Increasing number of regulatory approvals will have a positive impact on the growth of the overall market...

ALXN : 114.56 (-3.09%)
BAYRY : 11.6850 (-2.46%)
BMY : 57.94 (+0.03%)
GSK : 33.32 (-1.88%)
NVO : 63.38 (-4.45%)
Preeclampsia Diagnostics Market to Exhibit 11.0% CAGR and Touch USD 2.52 Billion by 2027; Increasing Healthcare Expenditure to Boost Growth: Fortune Business Insights(TM)

The global preeclampsia diagnostics market size is anticipated to gain momentum from the increasing number of pregnancies owing to the complete lockdown amid the COVID-19 pandemic. The report further states...

BAYRY : 11.6850 (-2.46%)
SIEGY : 63.7600 (-1.09%)
Global Animal Healthcare Market - Featuring Bayer AG, C. H. Boehringer Sohn AG & Co. KG, and Cadila Healthcare Ltd. Among Others | Technavio

The animal healthcare market is poised to grow by USD 7.98 billion during 2020-2024, progressing at a CAGR of over 4% during the forecast period.

BAYRY : 11.6850 (-2.46%)
Bayer Acquires Asklepios BioPharmaceutical to Broaden Innovation Base in Cell and Gene Therapy

Bayer AG today announced the acquisition of Asklepios BioPharmaceutical, Inc. (AskBio), a US-headquartered biopharmaceutical company specialized in the research, development and manufacturing of gene therapies...

BAYRY : 11.6850 (-2.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Key Turning Points

2nd Resistance Point 12.1332
1st Resistance Point 12.0566
Last Price 11.6850
1st Support Level 11.8467
2nd Support Level 11.7134

See More

52-Week High 21.5900
Fibonacci 61.8% 17.7929
Fibonacci 50% 16.6200
Fibonacci 38.2% 15.4471
Last Price 11.6850
52-Week Low 11.6500

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar